CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

Featuring perspectives from Dr Paul G Richardson, including the following topics:

• EXCALIBER-RRMM: A Phase III trial of iberdomide, daratumumab and dexamethasone for relapsed/refractory multiple myeloma (0:00)
  • Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract
• Phase III SUCCESSOR-1 and SUCCESSOR-2 studies evaluating mezigdomide-based regimens for relapsed/refractory multiple myeloma (8:24)
  • Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372.
  • Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070.
• EMN26: A Phase II study of maintenance therapy with iberdomide after autologous stem-cell transplantation for newly diagnosed multiple myeloma (13:34)
  • van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101.
• STOMP: A Phase I study of selinexor, mezigdomide and dexamethasone for patients with relapsed/refractory multiple myeloma who experienced relapse with or are ineligible for T-cell-redirecting therapy (24:53)
  • Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results. ASH 2025;Abstract 4010.

CME information and select publications